Article info

Download PDFPDF
Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non–small-cell lung cancer in China

Authors

  1. Correspondence to Mrs Yuan Jiang; jy_0609{at}163.com
View Full Text

Citation

Jiang Y, Wang X
Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non–small-cell lung cancer in China

Publication history

  • Received January 12, 2020
  • Revised June 8, 2020
  • Accepted June 23, 2020
  • First published July 31, 2020.
Online issue publication 
April 22, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.